RET fusion positive cancer
MONDO:0700216Neoplasm associated with expression of a RET (REarranged during Transfection) fusion. RET fusion-positive tumors have been identified in a broad range of solid tumor types, including multiple endocrine neoplasia 2 (MEN2), papillary thyroid carcinoma (PTC), non-small cell lung cancer (NSCLC), invasive breast cancers, and pancreatic ductal adenocarcinomas in addition to colorectal adenocarcinoma, melanoma, small cell lung cancer, neuroblastoma, and small intestine neuroendocrine tumors.
Also known as: RET fusion positive neoplasm, RET fusion positive solid tumor, RET fusion positive solid tumour
1444 clinical trials for this condition and its sub-types, 20 tagged with RET fusion positive cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New pill targets rare cancer drivers in chinese patients
Disease control OngoingThis phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and d…
Phase 2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Targeted pill shows promise for Hard-to-Treat lung cancer subtype
Disease control OngoingThis phase 3 trial tests an experimental drug called SY-5007 in people with advanced non-small cell lung cancer that has a specific genetic change (RET fusion). The drug is a daily pill designed to block the cancer-driving RET protein. The study aims to see how well the drug shri…
Phase 3 • Sponsor: Shouyao Holdings (Beijing) Co. LTD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets rare gene mutations in advanced cancers
Disease control OngoingThis study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug targets rare lung cancer mutation in advanced disease
Disease control OngoingThis phase II trial tests the drug selpercatinib (LOXO-292) in 124 people with stage IV or recurrent non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug works by blocking enzymes that help cancer cells grow. Researchers are measuring how ma…
Phase 2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for lung cancer patients: drug may delay return of disease
Disease control OngoingThis study tests whether the drug selpercatinib can delay the return of lung cancer in people with early-stage non-small cell lung cancer that has a specific genetic change (RET fusion). Participants have already had surgery or radiation to remove or treat their cancer. They will…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New pill targets rare genetic cancers in first human trial
Disease control OngoingThis early-stage study tests an experimental pill called APS03118 in adults with advanced solid tumors that have specific RET gene mutations or fusions. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 108 participants will…
Phase 1 • Sponsor: Applied Pharmaceutical Science, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo aims to outsmart Drug-Resistant lung cancer
Disease control OngoingThis study tests a new drug, amivantamab, combined with standard targeted therapies (TKIs) in people with advanced non-small cell lung cancer that has specific gene changes (ALK, ROS1, or RET). The goal is to see if this combination can overcome drug resistance and shrink tumors.…
Phase 1/2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New targeted therapy shows promise for rare lung cancer subtype
Disease control OngoingThis study tests a drug called selpercatinib against standard chemotherapy for people with a certain type of advanced lung cancer (RET fusion-positive non-small cell lung cancer). The goal is to see if selpercatinib can delay cancer growth better than current treatments. About 26…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Scientists dig into the DNA of drug-resistant lung cancers to find hidden clues
Knowledge-focused By invitation onlyThis study enrolls 40 people with non-small cell lung cancer whose tumors have stopped responding to targeted therapy (tyrosine kinase inhibitors). Researchers will analyze the tumors' full genetic code and RNA to find new resistance mechanisms. The goal is to better understand w…
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC